Antipsychotic-Induced Hypothermia After Starting Aripiprazole for Posttraumatic Agitation Management: A Case Report
Conclusions To our knowledge, this is the first publication detailing antipsychotic-induced hypothermia occurring in a TBI patient. Clinicians who initiate antipsychotics for posttraumatic agitation in a TBI patient should be aware of this potential adverse effect, as well as clinical presentation, evaluation, and management strategies. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Case Reports Source Type: research

Brexpiprazole-Associated Pisa Syndrome (Pleurothotonus) in a Patient With Dementia
Conclusions Drug-induced PS may be associated with dopamine-acetylcholine imbalance. This imbalance causes the dysfunction of the cortex and basal ganglia and the dysfunction of sensory and somatosensory system. Stopping the offending drugs is a choice for the treatment of PS. This is the first report of PS-induced brexpiprazole. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Case Reports Source Type: research

What Is the Medication Iatrogenic Risk in Elderly Outpatients for Chronic Pain?
Conclusion Elderly patients with chronic pain are at risk of medication iatrogeny. Preventive measures as multidisciplinary medication review could reduce the iatrogenic risk in these outpatients. This study is registered at clinicaltrials.gov as NCT04006444 on July 3, 2019. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

The Effect of Rotigotine on Cognitive Function, Daytime Sleepiness, and Sleep Problems in Parkinson Disease: An Open-Label Pilot Study
Background We hypothesized that rotigotine may have a positive effect on cognitive function in patients with Parkinson disease (PD) by improving daytime motor function and sleep status. Methods Fifteen PD patients with sleep disturbances, defined as a PD Sleep Scale (PDSS)-2 score of 15 or greater, were included in this single-center, 3-month open-label study. Participants received 2 to 4 mg/24 h (patch content: 4.5–9 mg) rotigotine for a 3-month period. At baseline and 3 months, the patients were evaluated on the Movement Disorder Society Revision of the Unified PD Rating Scale (MDS-UPDRS) parts III and IV an...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Assessment of Suvorexant and Eszopiclone as Alternatives to Benzodiazepines for Treating Insomnia in Patients With Major Depressive Disorder
Conclusions Switching to suvorexant or eszopiclone was well tolerated and improved the severity of benzodiazepine-unresponsive insomnia in MDD patients. Both drugs could be beneficial alternatives to benzodiazepines for treating insomnia in MDD patients. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Effectiveness and Safety of Early High-Efficacy Versus Escalation Therapy in Relapsing-Remitting Multiple Sclerosis in Argentina
Objective Escalation (ES) and early high-efficacy (EHE) therapies have been the main treatment strategies adopted in multiple sclerosis (MS) in recent years. The aim of this study was to compare the effectiveness and safety of EHE versus ES strategies in MS patients from Argentina. Methods This is a retrospective multicenter cohort study in Argentina. Eligible patients were categorized into 2 groups as follows: EHE if received natalizumab, ocrelizumab, rituximab, alemtuzumab, mitoxantrone, or cladribine; and ES if received interferon β, glatiramer acetate, teriflunomide, dimethyl fumarate, or fingolimod as init...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Effectiveness and Safety of Memantine for Headache: A Meta-analysis of Randomized Controlled Studies
Objective The effectiveness and safety of memantine for headache are elusive, and this meta-analysis aimed to explore the influence of memantine versus placebo for headache. Methods We searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through May 2021 and included randomized controlled trials reporting memantine versus placebo for headache patients. This meta-analysis was performed using the random-effects model. Results Our meta-analysis included 4 randomized controlled trials and 229 patients. Compared with control group for headache, memantine treatment could substantially ...
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Editorial
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - May 1, 2022 Category: Neurology Tags: Editorial Source Type: research

Metronidazole-Induced Toxic Neuropathy With the “Boomerang” Sign: A Case Report
Conclusions Clinicians should keep metronidazole toxicity in mind while dealing with a case of cytotoxic lesion of the corpus callosum with splenium involvement and peripheral neuropathy. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2022 Category: Neurology Tags: Case Reports Source Type: research

Pentobarbital Coma Use in a Pregnant Patient With Refractory Intracranial Hypertension: A Case Report
Conclusions Thus, we present the first case report demonstrating that pentobarbital coma may be a safe and efficacious option for treating pregnant patients with life-threatening refractory intracranial hypertension. We also provide dosing information for pentobarbital administration. Additional studies and reports involving pregnant patients are needed to better understand the impact of pentobarbital on both the mother and fetus. Furthermore, long-term follow-up of both the mother and newborn is critical to identifying any delayed sequelae of neonatal exposure to pentobarbital. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2022 Category: Neurology Tags: Case Reports Source Type: research

Clinical Management of Sleep and Sleep Disorders With Cannabis and Cannabinoids: Implications to Practicing Psychiatrists
Phytocannabinoid derivatives are among the several compounds found in the cannabis plant. The phytocannabinoid chemicals Δ9-tetrahydrocannabinol (THC) and cannabidiol are mostly responsible for the drug's behavioral effects. Chronic cannabis administration has been shown to disrupt circadian rhythms and reduce the duration of the deepest phase (stage N3) of nonrapid eye movement sleep. Cannabidiol is thought to be responsible for the disruption of the circadian rhythm, whereas THC is thought to be accountable for the changes in sleep architecture. The quality of one's sleep has a significant impact on cannabis abstinence ...
Source: Clinical Neuropharmacology - March 1, 2022 Category: Neurology Tags: Review Article Source Type: research

“The Triptan's Hangover”: A Multicentric Cross-sectional Observational Study of the Adverse Events of Triptans in Patients With Migraine
The emergence of triptans represented a breakthrough in the treatment of migraine, but in clinical practice, patients describe symptoms that resemble those of a hangover after taking them. We propose the use of the Hangover Symptoms Scale (HSS) to evaluate this syndrome in patients that take triptans, which may help identify patients at higher risk of presenting these adverse effects that may interfere with therapeutic compliance. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Effectiveness of Atomoxetine (Strattera) for the Treatment of Poststroke Aphasia Combined With Cognitive Impairment
Conclusions Atomoxetine has been shown to significantly improve cognitive function and language in patients with poststroke aphasia. It is also the first study to report improvement in auditory comprehension and naming by administration of atomoxetine. (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - March 1, 2022 Category: Neurology Tags: Original Articles Source Type: research

Misophonia Successfully Treated of With Fluoxetine: A Case Report: Erratum
No abstract available (Source: Clinical Neuropharmacology)
Source: Clinical Neuropharmacology - January 1, 2022 Category: Neurology Tags: Erratum Source Type: research

β-Blockers for the Treatment of Misophonia and Misokinesia
We present the first case of using a β-blocker (propranolol) to successfully treat a patient experiencing misophonia and misokinesia. A moderate dose (60 mg) of propranolol completely eliminated multiple auditory and visual trigger symptoms related to other people eating. His trigger response symptoms included overwhelming negative emotions and prominent sympathetic overactivity (fight-or-flight response). These symptoms were so severe that he had avoided most meals with friends and family for the past several years. Propranolol eliminated the emotional and physiological effects of both the auditory and visual triggers, w...
Source: Clinical Neuropharmacology - January 1, 2022 Category: Neurology Tags: Case Reports Source Type: research